Niacin as antidyslipidemic drug

被引:34
|
作者
Julius, Ulrich [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Internal Med 3, D-01307 Dresden, Germany
关键词
niacin; lipid disorders; intervention studies; cardiovascular end-points; adverse effects; EXTENDED-RELEASE NIACIN; LOW HDL/HIGH TRIGLYCERIDES; TRIAL ATHEROTHROMBOSIS INTERVENTION; APOLIPOPROTEIN-A-I; NICOTINIC-ACID; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; COMBINATION THERAPY; FATTY LIVER; LIPOPROTEIN(A) CONCENTRATION;
D O I
10.1139/cjpp-2014-0478
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Niacin is an important vitamin (B3) that can be used in gram doses to positively modify pathogenetically relevant lipid disorders: elevated LDL cholesterol, elevated non-HDL cholesterol, elevated triglycerides, elevated lipoprotein(a), and reduced HDL cholesterol. This review reports the latest published findings with respect to niacin's mechanisms of action on these lipids and its anti-inflammatory and anti-atherosclerotic effects. In the pre-statin era, niacin was shown to have beneficial effects on cardiovascular end-points; but in recent years, two major studies performed in patients whose LDL cholesterol levels had been optimized by a statin therapy did not demonstrate an additional significant effect on these end-points in the groups where niacin was administered. Both studies have several drawbacks that suggest that they are not representative for other patients. Thus, niacin still plays a role either as an additive to a statin or as a substitute for a statin in statin-intolerant patients. Moreover, patients with elevated triglyceride and low HDL cholesterol levels and patients with elevated lipoprotein(a) concentrations will possibly benefit from niacin, although currently the study evidence for these indications is rather poor. Niacin may be useful for compliant patients, however possible side effects (flushing, liver damage) and contraindications should be taken into consideration.
引用
收藏
页码:1043 / 1054
页数:12
相关论文
共 50 条
  • [31] THE KETOGENIC ACTION OF NIACIN AND THE ALCOHOL OF NIACIN
    JANES, RG
    PETERSON, IM
    ANATOMICAL RECORD, 1948, 101 (04): : 742 - 742
  • [32] Antidyslipidemic and antioxidant activity of Pinus roxburghii needles
    Puri, Anju
    Srivastava, Anuj K.
    Singhal, B.
    Mishra, S. K.
    Srivastava, S.
    Lakshmi, V.
    MEDICINAL CHEMISTRY RESEARCH, 2011, 20 (09) : 1589 - 1593
  • [33] Increased conversion ratio of tryptophan to niacin by the administration of clofibrate, a hypolipidemic drug, to rats
    Shibata, K
    Kondo, T
    Marugami, M
    Umezawa, C
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 1996, 60 (09) : 1455 - 1459
  • [34] Niacin
    Meyer-Ficca, Mirella
    Kirkland, James B.
    ADVANCES IN NUTRITION, 2016, 7 (03) : 556 - 558
  • [35] Novel coumarin derivatives as potential antidyslipidemic agents
    Sashidhara, Koneni V.
    Kumar, Abdhesh
    Kumar, Manoj
    Sonkar, Ravi
    Bhatia, Gitika
    Khanna, A. K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4248 - 4251
  • [36] Antidyslipidemic and antioxidant activity of Pinus roxburghii needles
    Anju Puri
    Anuj K. Srivastava
    B. Singhal
    S. K. Mishra
    S. Srivastava
    V. Lakshmi
    Medicinal Chemistry Research, 2011, 20 : 1589 - 1593
  • [37] The safety of niacin in the US Food and Drug Administration Adverse Event Reporting database
    Alsheikh-Ali, Alawi A.
    Karas, Richard H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8A): : 9B - 13B
  • [38] HYPERCHOLESTEROLEMIA - USE OF NIACIN AND NIACIN COMBINATIONS IN THERAPY
    RIVIN, AU
    CALIFORNIA MEDICINE, 1962, 96 (04): : 267 - &
  • [39] Antihyperglycemic and antidyslipidemic agent from Aegle marmelos
    Narender, T.
    Shweta, S.
    Tiwari, P.
    Reddy, K. Papi
    Khaliq, T.
    Prathipati, P.
    Puri, A.
    Srivastava, A. K.
    Chander, R.
    Agarwal, S. C.
    Raj, K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (06) : 1808 - 1811
  • [40] LACK OF PHARMACOKINETIC DRUG INTERACTION BETWEEN EZETIMBE/SIMVASTATIN AND EXTENDED RELEASE NIACIN
    Kosoglou, T.
    Zhu, V.
    Statkevich, P.
    Trianlafyllou, I.
    Taggart, W.
    Xuan, F.
    Kim, K.
    Culfer, D. L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1118 - 1118